Biological DMARDs Stabilize Bone Matrix Marker Pentosidine in Rheumatoid Arthritis Remission
Long-term longitudinal changes in bone matrix and turnover markers in rheumatoid arthritis: A retrospective cohort study.
Abstract
In rheumatoid arthritis patients aged ≥50, biological/targeted synthetic DMARDs prevented pentosidine increase in remission, suggesting better long-term bone quality.